{"zip": "60064-6400", "sector": "Healthcare", "fullTimeEmployees": 47000, "longBusinessSummary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Beh\u00c3\u00a7et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstr\u00c3\u00b6m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.", "city": "North Chicago", "phone": "847 932 7900", "state": "IL", "country": "United States", "companyOfficers": [], "website": "http://www.abbvie.com", "maxAge": 1, "address1": "1 North Waukegan Road", "industry": "Drug Manufacturers\u2014General", "previousClose": 112.21, "regularMarketOpen": 112.41, "twoHundredDayAverage": 107.83318, "trailingAnnualDividendYield": 0.032617416, "payoutRatio": 1.7993, "volume24Hr": null, "regularMarketDayHigh": 112.66, "navPrice": null, "averageDailyVolume10Day": 9592216, "totalAssets": null, "regularMarketPreviousClose": 112.21, "fiftyDayAverage": 113.20853, "trailingAnnualDividendRate": 3.66, "open": 112.41, "averageVolume10days": 9592216, "expireDate": null, "yield": null, "algorithm": null, "dividendRate": 5.2, "exDividendDate": 1618358400, "beta": 0.806398, "circulatingSupply": null, "startDate": null, "regularMarketDayLow": 110.85, "priceHint": 2, "currency": "USD", "trailingPE": 38.24236, "regularMarketVolume": 8100962, "lastMarket": null, "maxSupply": null, "openInterest": null, "marketCap": 196602052608, "volumeAllCurrencies": null, "strikePrice": null, "averageVolume": 7128006, "priceToSalesTrailing12Months": 3.9167655, "dayLow": 110.85, "ask": 0, "ytdReturn": null, "askSize": 1100, "volume": 8100962, "fiftyTwoWeekHigh": 118.28, "forwardPE": 8.0607815, "fromCurrency": null, "fiveYearAvgDividendYield": 4.18, "fiftyTwoWeekLow": 79.11, "bid": 0, "tradeable": false, "dividendYield": 0.045700002, "bidSize": 1100, "dayHigh": 112.66, "exchange": "NYQ", "shortName": "AbbVie Inc.", "longName": "AbbVie Inc.", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "isEsgPopulated": true, "gmtOffSetMilliseconds": "-14400000", "underlyingSymbol": null, "quoteType": "EQUITY", "symbol": "ABBV", "underlyingExchangeSymbol": null, "headSymbol": null, "messageBoardId": "finmb_141885706", "uuid": "73238d42-cdcc-3f92-8141-dd675addae10", "market": "us_market", "annualHoldingsTurnover": null, "enterpriseToRevenue": 5.574, "beta3Year": null, "profitMargins": 0.10278, "enterpriseToEbitda": 11.667, "52WeekChange": null, "morningStarRiskRating": null, "forwardEps": 13.82, "revenueQuarterlyGrowth": null, "sharesOutstanding": 1764829952, "fundInceptionDate": null, "annualReportExpenseRatio": null, "bookValue": 7.408, "sharesShort": 18705085, "sharesPercentSharesOut": 0.0106, "fundFamily": null, "lastFiscalYearEnd": 1609372800, "heldPercentInstitutions": 0.69948, "netIncomeToCommon": 5098999808, "trailingEps": 2.913, "lastDividendValue": null, "SandP52WeekChange": null, "priceToBook": 15.037797, "heldPercentInsiders": 0.00104, "nextFiscalYearEnd": 1672444800, "mostRecentQuarter": 1617148800, "shortRatio": 2.44, "sharesShortPreviousMonthDate": 1615766400, "floatShares": 1737786512, "enterpriseValue": 279765909504, "threeYearAverageReturn": null, "lastSplitDate": null, "lastSplitFactor": null, "legalType": null, "morningStarOverallRating": null, "earningsQuarterlyGrowth": 0.18, "dateShortInterest": 1618444800, "pegRatio": 1.97, "lastCapGain": null, "shortPercentOfFloat": 0.0106, "sharesShortPriorMonth": 16201312, "category": null, "fiveYearAverageReturn": null, "regularMarketPrice": 112.41, "logo_url": "https://logo.clearbit.com/abbvie.com"}